| Detected | Trial | Change |
|---|---|---|
| 2026-06-02 | NCT05231122 Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for… |
date change Primary completion pushed: 2026-12-30 -> 2027-03-15 |
| 2026-06-02 | NCT05231122 Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for… |
date change Completion pushed: 2026-12-30 -> 2027-03-15 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 2 | |||
| NCT05231122 | Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for… | Ovarian Clear Cell Adenocarcinoma | Recruiting |
| NCT06980038 | Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better… | Head and Neck Squamous Cell Carcinoma | Recruiting |
| Phase 1/2 | |||
| NCT05849480 | A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin… | Biliary Cancer | Recruiting |
| Phase 1 | |||
| NCT04616248 | In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in… | Anatomic Stage IV Breast Cancer AJCC v8 | Active, Not Recruiting |
| NCT04520711 | Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor… | Malignant Epithelial Neoplasms | Active, Not Recruiting |
| NCT05349890 | Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T… | Malignant Epithelial Neoplasms | Active, Not Recruiting |